Long-Term Analysis of Psilocybin in Cancer Patients With Distress
Richard Simoneaux
Oncology Times March 26, 2020 DOI: 10.1097/01.cot.0000660232.19098.7f (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Population | Cancer patients |
| Topics | Psilocybin |
| Keywords | Term time Distress Cancer Intensive care medicine Clinical psychology Hallucinogen |
| Key points | The text states that although earlier cancer detection generally improves survival, a cancer diagnosis often provokes significant psychological distress, and a significant number of cancer patients are ultimately affected by anxiety and depressive disorders. It further notes that these patients often exhibit existential distress, the term applied to mental stress in patients facing end-of-life issues. |
Abstract
With the technological advances that have been made in diagnostics for cancer, more disease is being detected at an earlier stage. Although this generally improves the patient's chances for survival, a diagnosis of cancer can often provoke significant psychological distress in patients. A significant number of cancer patients will ultimately be affected by conditions such as anxiety and depressive disorders. These cancer patients often exhibit existential distress, the term often applied to the mental stress observed in patients who are facing end-of-life issues.